Literature DB >> 24430359

Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.

Yanfeng Liu1, Pengcheng He, Feng Liu, Naicen Zhou, Xiaoyan Cheng, Lili Shi, Huachao Zhu, Jing Zhao, Yuan Wang, Mei Zhang.   

Abstract

Tetra-arsenic tetra-sulfide (As4S4) is an arsenic compound with antitumor activity, especially in acute promyelocytic leukemia (APL) that are resistant to retinoic acid (RA). Although recent studies have revealed that the therapeutic action of As4S4 is closely associated with the induction of cellular apoptosis, the exact molecular mechanism underlying this action in RA-resistant APL remains to be clarified. In this study, we found that As4S4-induced apoptosis was accompanied by reduced mRNA and protein expression of SET gene in RA-resistant NB4-R1 cells. Moreover, RNAi knockdown of SET gene further promoted As4S4-induced apoptosis, while SET overexpression recovered the cell viability, suggesting that As4S4 induces apoptosis through the reduction of SET protein in NB4-R1 cells. We also observed that the knockdown of SET gene resulted in the upregulation of protein phosphatase 2 (PP2A) expression and the downregulation of promyelocytic leukemia and retinoic acid receptor α fusion gene (PML-RARα) expression, which were enhanced by As4S4 treatments. By contrast, overexpression of SET gene resulted in PP2A downregulation and PML-RARα upregulation, which were abolished by As4S4 pretreatment. Since PP2A is a proapoptotic factor and PML-RARα is an antiapoptotic factor, our results suggest that As4S4-induced apoptosis in RA-resistant NB4-R1 cells is through the downregulation of SET protein expression, which, in turn, increases PP2A and reduces PML-RARα expressions to lead to cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430359     DOI: 10.1007/s13277-013-1452-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

2.  [A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia].

Authors:  Feng-rong Wang; Ya-qing Lou; Dao-pei Lu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2005-10

Review 3.  Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.

Authors:  Massimo Breccia; Francesco Lo-Coco
Journal:  Expert Opin Pharmacother       Date:  2012-04-03       Impact factor: 3.889

4.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

Review 5.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

Authors:  V Janssens; J Goris
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

6.  Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements.

Authors:  M Fornerod; J Boer; S van Baal; M Jaeglé; M von Lindern; K G Murti; D Davis; J Bonten; A Buijs; G Grosveld
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

Review 7.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

8.  [Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia].

Authors:  Jing-Zhi Wang; Yan-Rong Liu; Ya-Zhen Qin; Hao Jiang; Feng-Rong Wang; Li Bao; Dao-Pei Lu
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2003-10

9.  Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.

Authors:  S G Carlson; E Eng; E G Kim; E J Perlman; T D Copeland; B J Ballermann
Journal:  J Am Soc Nephrol       Date:  1998-10       Impact factor: 10.121

Review 10.  Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).

Authors:  Peter Baláž; Ján Sedlák
Journal:  Toxins (Basel)       Date:  2010-06-21       Impact factor: 4.546

View more
  4 in total

1.  Inhibition of STAT3/VEGF/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells.

Authors:  Hyemin Lee; Hyo-Jung Lee; Ill Ju Bae; Jeong Jin Kim; Sung-Hoon Kim
Journal:  Oncotarget       Date:  2017-10-19

2.  TAF-Iβ deficiency inhibits proliferation and promotes apoptosis by rescuing PP2A and inhibiting the AKT/GSK-3β pathway in leukemic cells.

Authors:  Yanfeng Liu; Yan Jia; Xiao Fu; Pengcheng He
Journal:  Exp Ther Med       Date:  2019-09-17       Impact factor: 2.447

3.  Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.

Authors:  Tao Zhang; Haojie Lu; Weijun Li; Ronggui Hu; Zi Chen
Journal:  Int J Mol Sci       Date:  2015-11-10       Impact factor: 5.923

4.  As4S4 Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway.

Authors:  Di Wu; Wei Dong; Kun Fang; Mengchang Wang
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.